AxoGen (0HKD) Share Price & Analysis
0HKD Stock Chart & Stats
- Day’s Range
- $48.20 - $49.70
- 52-Week Range
- $21.75 - $52.69
- Previous Close
- $49.57
- Volume
- 210
- Average Volume (3M)
- 1,239
- Market Cap
- $2.95B
- Enterprise Value
- $2.25B
- Total Cash (Recent Filing)
- $348.07M
- Total Debt (Recent Filing)
- $19.47M
- Price to Earnings (P/E)
- ―
- Beta
- 1.43
- Next Earnings
- Feb 23, 2027 (Est.)
- EPS Estimate
- 0.15
- Last Dividend Ex-Date
- Mar 15, 2022
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross Margins
Strong multi-year revenue growth combined with consistently high gross margins indicates attractive product economics and expanding demand for peripheral nerve repair. This supports reinvestment in commercial expansion, clinical evidence, and new indications while providing a durable foundation for improving earnings.
Payer Coverage Expansion
Near-universal commercial coverage can reduce reimbursement barriers and make Avance easier for surgeons and providers to adopt across eligible procedures. Broader coverage expands the company’s addressable utilization base and supports more durable procedure growth beyond individual account wins.
Portfolio Expansion Through NerveTape
Adding NerveTape broadens AxoGen’s product portfolio from grafts and protective devices into direct nerve repair, increasing the number of procedures its commercial organization can address. The product’s fit with existing sales infrastructure may strengthen market reach and long-term competitive positioning.
Bears Say
Persistent GAAP Losses
Despite strong revenue growth and improved adjusted results, persistent GAAP losses show that operating expenses remain ahead of the company’s current revenue base. Continued losses can constrain internally funded investment and make sustained profitability dependent on operating leverage and disciplined spending.
Gross Margin Pressure
Lower gross margins could moderate the earnings benefit of rapid sales growth, particularly as production changes address higher demand for long-length Avance. Pricing and yield initiatives may help, but management expects their benefits to flow through costs with a delay.
BioCircuit Integration And Overlap Risk
BioCircuit creates strategic expansion but also adds execution complexity as AxoGen integrates products, sales responsibilities, and customer relationships. Overlap with Axoguard offerings and assumed cannibalization could reduce incremental growth, while purchase accounting and integration demands may pressure near-term returns.
AxoGen News
0HKD FAQ
What was AxoGen’s price range in the past 12 months?
What is AxoGen’s market cap?
When is AxoGen’s upcoming earnings report date?
How were AxoGen’s earnings last quarter?
Is AxoGen overvalued?
Does AxoGen pay dividends?
What is AxoGen’s EPS estimate?
How many shares outstanding does AxoGen have?
What happened to AxoGen’s price movement after its last earnings report?
Which hedge fund is a major shareholder of AxoGen?
What is the TipRanks Smart Score and how is it calculated?
AxoGen Stock Smart Score
Company Description
AxoGen
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Michael D. Dale
- Employees
- 622
- Website
- www.axogeninc.com
- Address
- 13631 Progress Boulevard, Alachua, FL, 32615, US
AxoGen (0HKD) Earnings & Revenues
0HKD Company Deck
0HKD Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, supported by 26.2% year-over-year revenue growth, accelerating breast performance, improved adjusted profitability, expanded payer coverage, clinical-study progress, completion of the BioCircuit acquisition, and raised full-year revenue guidance. The principal challenges were lower year-over-year gross margin, expected fourth-quarter margin pressure, higher operating and acquisition-related costs, Aetna's utilization-management restriction, and future amortization and integration considerations. Highlights significantly outweighed lowlights.
View all GB:0HKD earnings summaries0HKD Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 6 |
| Technical Analysis | 3 | 1 | 6 |
| Moving Averages | 12 | 0 | 0 |